Table 3.
Positron emission tomography (PET) and Single photon emission computed tomography (SPECT) in DM1.
| Study | Modality (Tracer) | Estimated parameters | Group size | Age (M ±SD) [years] | Control group | Disease duration (M ±SD) [years] | CTG repeat length (range) | Correlation parameters |
|---|---|---|---|---|---|---|---|---|
| Fiorelli et al. (15) | PET (18FDG) | glucose consumption | 11 | 35.3 ± 11.2 | + | - | - | Cortical atrophy |
| Mielke et al. (64) | PET (18FDG) | glucose consumption | 3 | 42/50/59 | + | - | - | - |
| Chang et al. (16) | SPECT (133Xe, 99mTC-HMPAO) | CBF, perfusion | 22 (no congenital) | 36.6 ± 14.0 | + | 13.5 ± 6.9 | - | NPT (+) |
| Annane et al. (65) | PET (18FDG) | glucose consumption | 11 | 43 ± 12 | + | 250–5000 | CTG (+), plasma insulin level (+) | |
| Meola et al. (42) | PET (H2O15) | CBF | 11 | 42.7 ± 14.6* | + | 500–700* | - | |
| Takeda et al. (66) | SPECT | CBF | 2 | 35/55 | - | 25/19 | 1300 | - |
| Romeo et al. (69) | SPECT (99mTC-ECD/HMPAO) PET (18FDG) | perfusion/glucose consumption | 58 (+PET: 17) | 46 ± 15/+PET: 49 ± 9 | - | 12.2 ± 8.6 | + | MIRS (+) |
| Weber et al. (33) | PET (18FDG) | glucose consumption | 17 (no con-genital/early-onset) | 37.2 ± 14.2* | + | 16.0 ± 9.6* | - | NPT |
| Renard et al. (67) | PET (18FDG) | glucose consumption | 24 (no congenital) | 47 ± 12.5 | + | 19.1 ± 9.0 | 83–2000 | CTG, age at onset |
| Peric et al. (68) | PET (18FDG) | glucose consumption | 16 (no con-genital/late-onset) | 45.6 ± 9.6 | + | 21.8 ± 8.3 | - | NPT (+) |
CBF, cerebral blood flow; CTG, CTG repeat length; 18FDG, 18F-Fluordesoxyglucose; MIRS, muscular impairment rating scale; NPT, neuropsychological tests; PET, positron emission tomography; SPECT, single photon emission computed tomography; (+), positive or negative correlation was found;
*
data refer to whole DM1 study group, including patients that did not undergo PET.